Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805105 | 0.92 | BDKRB1 (0.34) | BRAFBDKRB1EGFRMAPK9MAPK10 | |
| SCHEMBL2806524 | 0.92 | BRAF (0.38) | DHODHBRAFBDKRB1EGFRMAPK9 | |
| SCHEMBL2809360 | 0.91 | BDKRB1 (0.33) | BRAFBDKRB1EGFRMAPK9MAPK10 | |
| SCHEMBL2808764 | 0.91 | CNR2 (0.38) | BRAFBDKRB1MAPK9MAPK10 | |
| SCHEMBL185331 | 0.90 | DHODH (0.35) | DHODHGPBAR1 | |
| SCHEMBL2804955 | 0.90 | PIK3CA (0.36) | DHODHBDKRB1EGFRMAPK10ABL1 | |
| SCHEMBL2804889 | 0.89 | MAPK9 (0.36) | DHODHBRAFBDKRB1MAPK9MAPK10 | |
| SCHEMBL2805743 | 0.87 | BDKRB1 (0.34) | BRAFBDKRB1EGFRMAPK9MAPK10 | |
| SCHEMBL2808302 | 0.85 | BACE1 (0.33) | BDKRB1MAPK9MAPK10 | |
| SCHEMBL2811232 | 0.83 | BRAF (0.36) | BRAFBDKRB1EGFRLCKKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | DHODH 2925/4885BRAF 3144/4885BDKRB1 289/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | DHODH 2925/4885BRAF 3144/4885BDKRB1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.